These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 17189881

  • 21. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 22. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
    Wang ZQ, Li L, Li R, Luo SY, Bai XQ, Liang QF, Deng SJ, Sun XG.
    Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
    [Abstract] [Full Text] [Related]

  • 23. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
    Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF.
    Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
    [Abstract] [Full Text] [Related]

  • 24. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Jan; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 25. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
    Park SH, Lim JA, Choi JS, Kim KA, Joo CK.
    Cornea; 2009 Jan; 28(1):68-72. PubMed ID: 19092409
    [Abstract] [Full Text] [Related]

  • 26. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM, Boeckh A, Simpson RB, Dubose K.
    J Vet Intern Med; 2006 Jan; 20(6):1297-306. PubMed ID: 17186841
    [Abstract] [Full Text] [Related]

  • 27. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS, Denton P, Osterhout GJ, Tuli S, O'Brien TP.
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
    Naber KG, Hollauer K, Kirchbauer D, Witte W.
    Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
    [Abstract] [Full Text] [Related]

  • 30. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R, Wagenaar JA, Walker RD.
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [Abstract] [Full Text] [Related]

  • 31. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
    Hesje CK, Borsos SD, Blondeau JM.
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D, Aoi H, Sugimoto K, Ueshima T, Amano H, Itoh K, Kuramoto Y, Yazaki A.
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
    Deramo VA, Lai JC, Fastenberg DM, Udell IJ.
    Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
    [Abstract] [Full Text] [Related]

  • 38. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
    Sanders ME, Moore QC, Norcross EW, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME.
    Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
    [Abstract] [Full Text] [Related]

  • 39. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S, Tunger A, Cilli F.
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [Abstract] [Full Text] [Related]

  • 40. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G, Alfonso EC, Miller D.
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.